FDA OKs eNeura’s mobile migraine treatment device

May 23, 2014 By Arezu Sarvestani Leave a Comment

FDA OKs eNeura's mobile migraine treatment device

Maryland medical device maker eNeura today touted FDA clearance for its SpringTMS system, a mobile magnetic stimulator that can help relieve pain associated with migraines that are preceded by an ‘aura.’

The device is the 1st of its kind to use transcranial magnetic stimulation to depolarize neurons on the brain, a process that doctors believe may interrupt migraine activity. Designed for home use, patients place the device against the back of the head, where a magnetic pulse targets the occipital lobe.

Clearance was based on eNeura’s double-blind, placebo-controlled studies in more than 200 patients, which found that nearly 38% of eTMS patients were pain-free 2 hours after using the device, compared with only 17% of patients in the control group. About 34% of eTMS patients were pain-free after 24 hours, compared with 10% of the control patients. Researchers reported no device-related serious adverse events.

"No discernible evidence exists to suggest that [single-pulse] TMS causes harm to humans," researchers wrote in a 2010 study of migraine patients, published in Headache, The Journal of Head & Face Pain.

The SpringTMS device is eNeura’s 2nd generation of migraine-treating TMS technology, following the Cerena system which won FDA clearance late last year. SpringTMS is built on the same technology, but is more portable.

"The FDA clearance of SpringTMS is a significant accomplishment for eNeura and a tremendous validation of our sTMS technology. We are very confident that SpringTMS will offer tremendous benefit to many migraine sufferers," president & CEO Dr. David Rosen said in prepared remarks. "We are excited to introduce this new treatment to patients in the U.S. through our post-market open-label study with leading headache specialists. This strategy will ensure we approach the market in a manner that enables the best outcome for patients using our device."

The device maker is on a roll lately, having just raised $1.6 million in a hoped-for $2 million funding round after raising $2.2 million in January.

The FDA has rubber-stamped a handful of migraine devices in recent months. In March the agency approved the Cefaly headband technology for daily use in prevention of migraine headaches.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston

At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.

Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.

REGISTER NOW

FDA panel: Neuronix Alzheimer’s therapy fails to prove efficacy
An FDA advisory panel has recommended against granting de novo clearance to Neuronix’s NeuroAD system intended to slow the progress of mild to moderate Alzheimer’s disease. NeuroAD is approved for use in Europe, Australia and Israel, but the panel found that while it met FDA safety standards, clinical studies did not prove that it is… […]
Instron launches biomedical testing online training course
Instron (Norwood, Mass.) recently announced that it is foddering an online training program, “The Essentials of Biomedical Testing.” The course is designed to give an introduction and foundation to biomedical testing. It is an hour long course geared toward lab managers and test machine operators who work in the biomedical industry as well as test… […]
Linak touts new touch screen control for hospital beds
Linak has launched a new touch screen control for advanced hospital bets. The new touch screen is a large screen for the ACT controller to give users a view of all functions through an easy-to-use format. The controller also offers three levels of operation, which includes care mode for patients and relatives, extended care… […]
Myomo inks Italian sales deal
Myomo recently announced that it has signed a sales and service agreement with Progettiamo Autonomia Robotics (PAR) to market the MyoPro in Italy. Myomo is a wearable medical robotics company that gives functionality to people who have neurological disorders and upper limb paralysis. PAR is also focused on neurological pathologies and delivering devices for orthopedic… […]
Artificial intelligence and medicine: Is it overhyped?
Artificial intelligence raises exciting possibilities for healthcare, but are companies promising more than they can deliver? AI could possibly fuel the future of medtech, enabling such thrilling innovations as implanted devices that instantly react to minute changes, software that can identify the best treatment options for individuals facing life-threatening conditions and fully-functioning autonomous surgical systems.… […]
ACell signs South Korean distribution agreement
ACell (Columbia, Md.) announced that it has signed an exclusive distribution agreement with MyungMoon Bio to market ACell’s wound matrix devices in South Korea. “South Korea is one of the largest healthcare markets in the Asia Pacific, and this agreement will meet a growing unmet need for innovative wound management solutions in the country,” Nino… […]
VisionCare wins approval for CentraSight implant in Australia
VisionCare (Saratoga, Calif.) recently announced that it has received regulatory approval from the Australian Department of Health Therapeutic Goods Administration for its Implantable Miniature Telescope. The miniature telescope is designed to improve the visual acuity in patients who are 55 years or older and have bilateral moderate to profound central vision impairment because of age-related… […]
Millstone Medical appoints new EVP of sales and business development
Millstone Medical announced that it has appointed Richard Worthen as its executive VP of sales and business development at its Massachusetts headquarters. Prior to joining Millstone Medical, Worthen served as VP of North American sales at Clozex Medical where he helped launch the company’s Class I skin closure device. He has also held a number… […]
SMC expands Wisconsin facility capabilities
SMC recently announced that it is expanding is drug delivery device capabilities by adding a pharmaceutical class 7 cleanroom at its Somerset, Wisc. facility. “As we continue to experience growth in the pharmaceutical market, we realized the need for additional clean room capabilities in our Somerset, Wisc. location,” Chetan Patel, CEO of SMC, said. “The… […]
March 2019 Issue: Can AI truly transform medicine?
Medtech is going digital: So how do we keep it real? One of medtech veteran Mir Imran’s biggest claims to fame is that, as a young engineer in the early 1980s, he played a pivotal role in the development of the first implantable ICD. Imran told me a startling fact a few years ago: FDA… […]
NE Ohio biomedical industry investments on the rise
Investment in the northeast Ohio biomedical sector totaled nearly $294 million in 2018 with 71 regional companies receiving funding, according to regional healthcare trade group BioEnterprise. Those figures make this region the third largest for total healthcare investment in the Midwest, following Minneapolis ($664 million) and Chicago ($551 million). These were among the findings of… […]